GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Price-to-Owner-Earnings

EV Biologics (EV Biologics) Price-to-Owner-Earnings : (As of May. 21, 2024)


View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Price-to-Owner-Earnings?

As of today (2024-05-21), EV Biologics's share price is $0.5541. EV Biologics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for EV Biologics's Price-to-Owner-Earnings or its related term are showing as below:


YECO's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.465
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-21), EV Biologics's share price is $0.5541. EV Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2017 was $-3.55. Therefore, EV Biologics's PE Ratio for today is At Loss.

As of today (2024-05-21), EV Biologics's share price is $0.5541. EV Biologics's EPS without NRI for the trailing twelve months (TTM) ended in was $15.85. Therefore, EV Biologics's PE Ratio without NRI for today is 0.03.

During the past 5 years, EV Biologics's highest PE Ratio without NRI was 0.03. The lowest was 0.00. And the median was 0.00.


EV Biologics Price-to-Owner-Earnings Historical Data

The historical data trend for EV Biologics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Price-to-Owner-Earnings Chart

EV Biologics Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17
Price-to-Owner-Earnings
- - - - -

EV Biologics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17 Dec17
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of EV Biologics's Price-to-Owner-Earnings

For the Biotechnology subindustry, EV Biologics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EV Biologics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EV Biologics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where EV Biologics's Price-to-Owner-Earnings falls into.



EV Biologics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

EV Biologics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.5541/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EV Biologics  (OTCPK:YECO) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


EV Biologics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of EV Biologics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


EV Biologics (EV Biologics) Business Description

Traded in Other Exchanges
N/A
Address
1621 Central Avenue, Cheyenne, WY, USA, 82001
EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.
Executives
Daniel S Mckinney director, 10 percent owner, officer: CEO TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan director C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3

EV Biologics (EV Biologics) Headlines

From GuruFocus

EV Biologics Updates on NFT Dividend

By ACCESSWIRE ACCESSWIRE 11-12-2021

EV Biologics Updates Shareholders on Name and Symbol Change

By ACCESSWIRE ACCESSWIRE 05-19-2021

EV Biologics NFT Dividend Update

By ACCESSWIRE ACCESSWIRE 07-19-2021

EV Biologics Updates on FINRA

By ACCESSWIRE ACCESSWIRE 01-18-2022

EV Biologics Signs MSA with LONZA Cell & Gene Therapy

By ACCESSWIRE ACCESSWIRE 05-17-2022

EV Biologics Launches Excyte with $100 million Valuation

By ACCESSWIRE ACCESSWIRE 08-15-2022

EV Biologics Briefs Shareholders on Market Cap Peer Comparison

By ACCESSWIRE ACCESSWIRE 08-12-2021